The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment

Atherosclerosis

Volumn 144, Issue 1, 1999, Pages 263-270

  Riegger, G ^a   Abletshauser, C ^b   Ludwig, M ^c   Schwandt, P ^d   Widimsky, J ^e   Weidinger, G ^b   Welzel, D ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Cardiac events; Fluvastatin; Lipid lowering; Symptomatic coronary heart disease

Indexed keywords

ANTIANGINA PECTORIS AGENT; CHOLESTEROL; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; EXERCISE TOLERANCE; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ST SEGMENT DEPRESSION; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; CORONARY VESSELS; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INDOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 0033016149     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00062-3     Document Type: Article

References (35)

1. LaRosa JC, Hunninghake D, Grundy SM, Wilson PW, Clarkson TB, Hay JW. The cholesterol facts. A summary of the evidence relating dietary habits, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation 1990;81:1721-33.
2. Neaton JD, Wentworth DF. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med 1992;152:56-63.
3. Fuster V, Badimon L, Badimon J, Chesebro JH. The pathogene sis of coronary artery disease and the acute coronary syndromes (1). New Engl J Med 1992;326:242-50.
4. Fuster V, Badimon L, Badimon J, Chesebro JH. The pathogene sis of coronary artery disease and the acute coronary syndromes (2). New Engl J Med 1992;326:310-8.
5. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Intern Med 1993;119:969-76.
6. Waters D, Higgenson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor upon the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT). Circulation 1994;89:959-68.
7. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
8. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995:91:2528-40.
9. Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the Carotid arteries (PLAC-II). Am J Cardiol 1995;75:455-9.
10. Haskell WL, Alderman EL, Fair JM, et al. Effects of multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994:89:975-90.
11. Blankenhorn DH, Nessim A, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Benefical effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc 1987;257:3233-40.
12. Shepherd J, Cobbe SJ, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301-7.
13. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevatidons (Lipoprotein and coronary atherosclerosis study (LCAS)). Am J Cardiol 1997;80:278-86.
14. Study group, European Atherosclerosis Society. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-600.
15. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-504.
16. Pignoli P, Tremoli F, Poli A, Oregte PL, Paoletti R. Intimal plus medial thickness of arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-406.
17. Ludwig M, Stumpe KO, Sauer A, Kolloch R, Goertz U, Vetter H. Short-term high dietary cholesterol in early life induces persistent increase in arterial wall thickness and vascular reactivity to noradrenaline. Klin Wochenschr 1989;67:442-6.
18. Watts GF, Lewis B, Brunt JNH. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
19. Brown BG, Albers JJ, Fisher LD. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med 1990;323:1289-98.
20. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease. Factors limiting achievement of goals. Am J Med 1995;100:197-204.
21. Marcelino JJ, Feingold KR. Inadequate treatment with HMGCoA reductase inhibitors by health care providers. Am J Med 1996;100:605-10.
22. Ornish D, Brown S, Scherwitz L, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129-33.
23. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995;76:86C-92.
24. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
25. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Atheriosclerosis, American Heart Association. Circulation 1995;92:1355-74.
26. Yokota T, Hansson GK. Immunological mechanisms in atherosclerosis. J Intern Med 1995;238:479-89.
27. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-7.
28. Eichstädt HW, Eskötter H, Hoffmann I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by shortterm fluvastatin in coronary artery disease. Am J Cardiol 1995;76:122A-5A.
29. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmilz G, Schmieder R. Improved endothelial function after lipid lowering therapy in hypercholesterolemic patients is mediated by increased bioavailability of nitric oxide. Circulation 1998;98:211-6.
30. Rothe G, Herr A, Stöhr J, Abletshauser C, Weidinger G, Schmilz G. A more mature phenolype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic palienls with coronary artery disease. Atherosclerosis 1999;144:251-61.
31. Katznelson S, Kobashigawa JA. Dual roles of HMG-CoA reduclase inhibitors in solid organ transplantation: lipid-lowering and immunosuppression. Kidney Int 1995;48:112-5.
32. Bestehorn HP, Rensing UFE, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter coronary intervention study (CIS). Eur Heart J 1997;18:226-34.
33. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events. Longterm follow-up from the cholesterol lowering atherosclerosis study. Circulation 1996;93:34-41.
34. Gnasso A, Irace C, Mattioli PL, Pujia A. Carotid intima-media thickness and coronary heart disease risk factors. Atherosclerosis 1996;119:7-15.
35. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimalmedial thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke 1993;24:1297-304.